Fig. 3From: The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ ageForest plot of the association between TMB and PFS in young and elderly patients in NSCLC. TMB: tumor mutation burden; PFS: progression-free survival; NSCLC: non-small cell lung cancer; HR: hazard ratio; CI: confidence intervalBack to article page